Skip to main content
. 2020 Aug 14;9:e52558. doi: 10.7554/eLife.52558

Figure 5. Loss of mitochondrial pyruvate carrier does not affect CL-316,243-stimulated increase in 13C-glycolytic flux.

(a) Western blot analysis of differentiated brown Mpc1F/F adipocytes expressing pMSCV2 or CreERT2 treated with ethanol or 4-hydroxy tamoxifen. N = 3. (b) Gene expression analysis in differentiated brown Mpc1F/F adipocytes expressing pMSCV2 or CreERT2 treated with ethanol or 4-hydroxy tamoxifen N = 3. (c) Atom mapping for [U-13C]-glucose tracing incorporation into the glycolytic intermediates. White circles are 12C atoms. Black circles are 13C atoms. (d) [U-13C]-glucose labeling in Mpc1F/F adipocytes expressing CreERT2 treated with ethanol or 4-hydroxy tamoxifen, with/without 100 nM CL-316,243 for 5 hours(N = 6). (e) Steady state levels of glycolytic intermediates in Mpc1F/F adipocytes expressing CreERT2 treated with ethanol or 4-hydroxy tamoxifen, with/without 100 nM CL-316,243 for 5 hours (N = 6).

Figure 5.

Figure 5—figure supplement 1. Isotopic labeling of glycolitic intermediates in brown adiopcytes labeled with [U-13C]-glucose.

Figure 5—figure supplement 1.

(a) Labeling pattern of [U-13C]-glucose incorporation into the glycolytic intermediates in MPC1F/F adipocytes expressing CreERT2 treated with ethanol or 4-hydroxy tamoxifen, with/without 100 nM CL-316,243 for 5 hours (N = 6). Results are expressed as fraction of pool. (b) Total media pyruvate and lactate from Mpc1F/F adipocytes expressing CreERT2 treated with ethanol or 4-hydroxy tamoxifen, with/without 100 nM CL-316,243 for 5 hours in [U-13C] glucose (N = 6).